PRQR ProQR Therapeutics N.V.

8.25
+0.02  (+0%)
Previous Close 8.23
Open 8.24
Price To Book 4.83
Market Cap 407,283,855
Shares 49,367,740
Volume 156,325
Short Ratio
Av. Daily Volume 309,244
Stock charts supplied by TradingView

NewsSee all news

  1. ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  2. ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  3. ProQR to Present at Upcoming Scientific Conferences

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the

  4. ProQR to Present at Upcoming Investor Conferences

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the

  5. ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

    Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020QR-1123 Investigational New Drug

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 data due 1H 2021.
Sepofarsen (QR-110 ) ILLUMINATE
Leber's Congenital Amaurosis (LCA) - Genetic blindness
Phase 1b top-line data released September 25, 2017. FEV levels not significant across four doses. One of four doses showed significance in subgroup.
QR-010
Cystic Fibrosis
Phase 1/2 interim analysis announced March 26, 2019. Future development to be conducted by Wings Therapeutics.
QR-313
Epidermolysis bullosa
Phase 1/2 initiation of dosing announced December 11, 2019. Data due 2021.
QR-1123
autosomal dominant retinitis pigmentosa (adRP)
Phase 1/2 interim data due 1Q 2020.
QR-421a - STELLAR
Usher Syndrome Type 2

Latest News

  1. ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  2. ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  3. ProQR to Present at Upcoming Scientific Conferences

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the

  4. ProQR to Present at Upcoming Investor Conferences

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the

  5. ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

    Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020QR-1123 Investigational New Drug

  6. ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA

  7. ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  8. ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

    Reported rapid, significant and durable improvements in vision at twelve monthsConcordant improvement in key secondary outcome measuresThe target registration dose of sepofarsen was well-tolerated with a favorable

  9. ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

    LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for

  10. ProQR to Present at Two Investor Conferences in October

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the

  11. ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the